Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Assets (2020 - 2025)

Historic Current Assets for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $28.8 million.

  • Ovid Therapeutics' Current Assets fell 5621.25% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year decrease of 5621.25%. This contributed to the annual value of $55.9 million for FY2024, which is 4895.89% down from last year.
  • Per Ovid Therapeutics' latest filing, its Current Assets stood at $28.8 million for Q3 2025, which was down 5621.25% from $42.1 million recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Current Assets high stood at $236.7 million for Q1 2021, and its period low was $28.8 million during Q3 2025.
  • Its 5-year average for Current Assets is $120.1 million, with a median of $109.6 million in 2023.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 38938.92% in 2021, then plummeted by 5621.25% in 2025.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Current Assets stood at $190.5 million in 2021, then tumbled by 31.03% to $131.4 million in 2022, then decreased by 16.58% to $109.6 million in 2023, then tumbled by 48.96% to $55.9 million in 2024, then crashed by 48.47% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q3 2025, $42.1 million for Q2 2025, and $45.9 million during Q1 2025.